Search by Drug Name or NDC
NDC 51672-2101-02 Jock Itch 10 mg/g Details
Jock Itch 10 mg/g
Jock Itch is a TOPICAL CREAM in the HUMAN OTC DRUG category. It is labeled and distributed by Taro Pharmaceuticals U.S.A., inc.. The primary component is BUTENAFINE HYDROCHLORIDE.
Product Information
NDC | 51672-2101 |
---|---|
Product ID | 51672-2101_a0159f92-c609-486b-a727-bc4d431ed8eb |
Associated GPIs | |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | Jock Itch |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Butenafine Hydrochloride |
Product Type | HUMAN OTC DRUG |
Dosage Form | CREAM |
Route | TOPICAL |
Active Ingredient Strength | 10 |
Active Ingredient Units | mg/g |
Substance Name | BUTENAFINE HYDROCHLORIDE |
Labeler Name | Taro Pharmaceuticals U.S.A., inc. |
Pharmaceutical Class | Benzylamine Antifungal [EPC], Benzylamines [CS] |
DEA Schedule | n/a |
Marketing Category | ANDA |
Application Number | ANDA205181 |
Listing Certified Through | 2024-12-31 |
Package
Package Images

NDC 51672-2101-02 (51672210102)
NDC Package Code | 51672-2101-2 |
---|---|
Billing NDC | 51672210102 |
Package | 1 TUBE in 1 CARTON (51672-2101-2) / 30 g in 1 TUBE |
Marketing Start Date | 2017-11-17 |
NDC Exclude Flag | N |
Pricing Information | N/A |
Standard Product Labeling (SPL)/Prescribing Information SPL 14a23a39-b567-4db4-bac0-c008c0ca6171 Details
Uses
Warnings
Directions
- adults and children 12 years and older:
- use the tip of the cap to break the seal and open the tube
- wash the affected skin with soap and water and dry completely before applying
- apply once a day to affected skin for 2 weeks or as directed by a doctor
- wash hands after each use
- children under 12 years: ask a doctor
Other information
Inactive ingredients
PRINCIPAL DISPLAY PANEL - 15 g Tube Carton
INGREDIENTS AND APPEARANCE
JOCK ITCH
butenafine hydrochloride cream |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Labeler - Taro Pharmaceuticals U.S.A., inc. (145186370) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
Taro Pharmaceuticals Inc. | 206263295 | MANUFACTURE(51672-2101) |
Revised: 11/2017
Document Id: a0159f92-c609-486b-a727-bc4d431ed8eb
Set id: 14a23a39-b567-4db4-bac0-c008c0ca6171
Version: 4
Effective Time: 20171120